Compounds > nicotine
Page last updated: 2024-08-26

nicotine and alpha-synuclein

nicotine has been researched along with alpha-synuclein in 11 studies

Research

Studies (11)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (18.18)29.6817
2010's6 (54.55)24.3611
2020's3 (27.27)2.80

Authors

AuthorsStudies
Hirohata, M; Ono, K; Yamada, M1
Fink, AL; Hong, DP; Uversky, VN1
Dmitriev, O; Kakish, J; Lee, JS; Nokhrin, S; Tavassoly, O1
Jakova, E; Lee, JS1
Kardani, J; Roy, I; Sethi, R1
Bernstein, AI; Cai, H; Caudle, WM; Dunn, AR; Hoffman, CA; Li, Y; Lohr, KM; Miller, GW; Ozawa, M; Sastry, N; Sgobio, C; Stout, KA; Wang, M1
Bove, N; Chesselet, MF; Dutta, G; Elias, CJ; Lemesre, V; Lester, HA; Magen, I; Subramaniam, SR; Zhu, C1
Barbon, A; Bellucci, A; Bono, F; Fiorentini, C; Missale, C; Mutti, V; Savoia, P1
Lao-Kaim, NP; Piccini, P; Roussakis, AA; Zeng, Z1
Clemens, SG; Feany, MB; Olsen, AL1
Dulcis, D; Keisler, M; Lai, JI; Manfredsson, FP; Porcu, A; Powell, SB; Romoli, B1

Reviews

1 review(s) available for nicotine and alpha-synuclein

ArticleYear
Astrocytes in Parkinson's disease: from preclinical assays to in vivo imaging and therapeutic probes.
    Neurobiology of aging, 2020, Volume: 95

    Topics: Aging; alpha-Synuclein; Antioxidants; Astrocytes; Cholinergic Agonists; Disease Progression; Gliosis; Glutathione; Humans; Nerve Growth Factors; Nicotine; Parkinson Disease; Purinergic Antagonists; Risk Factors

2020

Other Studies

10 other study(ies) available for nicotine and alpha-synuclein

ArticleYear
Anti-fibrillogenic and fibril-destabilizing activity of nicotine in vitro: implications for the prevention and therapeutics of Lewy body diseases.
    Experimental neurology, 2007, Volume: 205, Issue:2

    Topics: alpha-Synuclein; Benzothiazoles; Humans; Kinetics; Lewy Body Disease; Microfibrils; Microscopy, Atomic Force; Microscopy, Electron; Mutation; Nicotine; Nicotinic Agonists; Pyridines; Pyrrolidines; Reverse Transcriptase Polymerase Chain Reaction; Spectrometry, Fluorescence; Thiazoles

2007
Smoking and Parkinson's disease: does nicotine affect alpha-synuclein fibrillation?
    Biochimica et biophysica acta, 2009, Volume: 1794, Issue:2

    Topics: alpha-Synuclein; Amino Acid Sequence; Anabasine; Benzothiazoles; Chromatography, Gel; Cotinine; Humans; Hydroquinones; Microscopy, Atomic Force; Molecular Sequence Data; Mutation; Nicotine; Parkinson Disease; Protein Binding; Protein Multimerization; Smoking; Thiazoles

2009
The use of nanopore analysis for discovering drugs which bind to α-synuclein for treatment of Parkinson's disease.
    European journal of medicinal chemistry, 2014, Dec-17, Volume: 88

    Topics: alpha-Synuclein; Binding Sites; Biological Products; Caffeine; Calorimetry; Drug Discovery; Humans; Molecular Conformation; Nanopores; Nicotine; Nuclear Magnetic Resonance, Biomolecular; Parkinson Disease; Protein Folding; Structure-Activity Relationship

2014
Behavior of α-synuclein-drug complexes during nanopore analysis with a superimposed AC field.
    Electrophoresis, 2017, Volume: 38, Issue:2

    Topics: alpha-Synuclein; Caffeine; Electricity; Electrophoresis; Humans; Metformin; Models, Chemical; Nanopores; Nicotine; Parkinson Disease; Pharmaceutical Preparations

2017
Nicotine slows down oligomerisation of α-synuclein and ameliorates cytotoxicity in a yeast model of Parkinson's disease.
    Biochimica et biophysica acta. Molecular basis of disease, 2017, Volume: 1863, Issue:6

    Topics: alpha-Synuclein; Humans; Lewy Bodies; Models, Biological; Nicotine; Parkinson Disease; Protein Multimerization; Saccharomyces cerevisiae

2017
Synaptic vesicle glycoprotein 2C (SV2C) modulates dopamine release and is disrupted in Parkinson disease.
    Proceedings of the National Academy of Sciences of the United States of America, 2017, 03-14, Volume: 114, Issue:11

    Topics: Aged; Aged, 80 and over; alpha-Synuclein; Animals; Basal Ganglia; Biomarkers; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Female; Gene Deletion; Gene Expression; Humans; Locomotion; Male; Membrane Glycoproteins; Mice; Mice, Knockout; Mice, Transgenic; Middle Aged; Nerve Tissue Proteins; Nicotine; Parkinson Disease; Protein Binding; Synaptic Vesicles

2017
Chronic nicotine improves cognitive and social impairment in mice overexpressing wild type α-synuclein.
    Neurobiology of disease, 2018, Volume: 117

    Topics: alpha-Synuclein; Animals; Cognition Disorders; Drug Administration Schedule; Gene Expression; Humans; Mice; Mice, Transgenic; Nicotine; Nicotinic Agonists; Social Behavior Disorders

2018
Nicotine prevents alpha-synuclein accumulation in mouse and human iPSC-derived dopaminergic neurons through activation of the dopamine D3- acetylcholine nicotinic receptor heteromer.
    Neurobiology of disease, 2019, Volume: 129

    Topics: alpha-Synuclein; Animals; Cells, Cultured; Dopaminergic Neurons; Humans; Induced Pluripotent Stem Cells; Mice; Mice, Inbred C57BL; Mice, Knockout; Neuroprotective Agents; Nicotine; Receptors, Dopamine D3; Receptors, Nicotinic

2019
Nicotine-Mediated Rescue of α-Synuclein Toxicity Requires Synaptic Vesicle Glycoprotein 2 in Drosophila.
    Movement disorders : official journal of the Movement Disorder Society, 2023, Volume: 38, Issue:2

    Topics: alpha-Synuclein; Animals; Dopaminergic Neurons; Drosophila; Glycoproteins; Humans; Nicotine; Parkinson Disease; Synaptic Vesicles

2023
Nicotine-Mediated Recruitment of GABAergic Neurons to a Dopaminergic Phenotype Attenuates Motor Deficits in an Alpha-Synuclein Parkinson's Model.
    International journal of molecular sciences, 2023, Feb-20, Volume: 24, Issue:4

    Topics: alpha-Synuclein; Animals; Dopamine; Dopaminergic Neurons; GABAergic Neurons; Mice; Nicotine; Parkinson Disease; Phenotype; Substantia Nigra

2023